Johnson & Johnson $JNJ Shares Purchased by IFM Investors Pty Ltd

Key Points

• IFM Investors Pty Ltd increased its stake in Johnson & Johnson by 3.3% in the first quarter, adding 15,989 shares and bringing its total holdings to 505,534 shares worth about $123.6 million.
• Johnson & Johnson reported solid quarterly results, with EPS of $2.70 topping estimates and revenue of $24.06 billion, up 9.9% year over year. The company also raised its FY 2026 EPS guidance to $11.45-$11.65.
• The company boosted its quarterly dividend to $1.34 per share, up from $1.30, implying a $5.36 annualized payout and a 2.0% yield. Analysts remain broadly constructive, with a consensus rating of “Moderate Buy” and an average target price of $256.70.

IFM Investors Pty Ltd grew its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 3.3% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 505,534 shares of the company's stock after buying an additional 15,989 shares during the quarter. Johnson & Johnson accounts for 1.0% of IFM Investors Pty Ltd's portfolio, making the stock its 14th largest position. IFM Investors Pty Ltd's holdings in Johnson & Johnson were worth $123,573,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in the business. Auto Owners Insurance Co lifted its holdings in shares of Johnson & Johnson by 22,225.6% during the 4th quarter. Auto Owners Insurance Co now owns 69,419,308 shares of the company's stock valued at $1,436,633,000 after acquiring an additional 69,108,368 shares in the last quarter. Norges Bank purchased a new stake in Johnson & Johnson during the 4th quarter worth $6,924,523,000. Capital World Investors acquired a new stake in Johnson & Johnson in the 4th quarter valued at $2,005,942,000. Diamant Asset Management Inc. lifted its stake in shares of Johnson & Johnson by 24,436.5% during the first quarter. Diamant Asset Management Inc. now owns 4,473,008 shares of the company's stock worth $109,338,000 after purchasing an additional 4,454,778 shares in the last quarter. Finally, Vanguard Group Inc. boosted its position in shares of Johnson & Johnson by 1.6% in the fourth quarter. Vanguard Group Inc. now owns 240,349,660 shares of the company's stock worth $49,740,362,000 after buying an additional 3,731,074 shares during the period. Institutional investors and hedge funds own 69.55% of the company's stock.

Insider Buying and Selling

In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 10,000 shares of Johnson & Johnson stock in a transaction on Thursday, June 11th. The shares were sold at an average price of $241.15, for a total value of $2,411,500.00. Following the completion of the transaction, the executive vice president owned 114,288 shares of the company's stock, valued at $27,560,551.20. The trade was a 8.05% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. 0.16% of the stock is currently owned by corporate insiders.

Trending Headlines about Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Members of Congress have been buying J&J shares, which can signal confidence in the company’s prospects and may attract attention from retail investors. Members of Congress Are Loading Up on Johnson & Johnson and UnitedHealth. Here's Why Retail Investors Should Pay Attention.
• Positive Sentiment: Johnson & Johnson launched its Dual-Energy THERMOCOOL SMARTTOUCH SF cardiac ablation platform in Europe, adding a commercial growth catalyst in its medtech business. Johnson & Johnson (JNJ) Launches Dual-Energy Cardiac Ablation Catheter in Europe
• Positive Sentiment: J&J is being highlighted as a top dividend and defensive healthcare name, with articles pointing to its reliable cash flow, dividend profile, and long-term appeal. Johnson & Johnson (JNJ): Focused on Cancer and Neuroscience as a Top Dividend Aristocrat Stock to Buy
• Positive Sentiment: Recent updates say J&J is strengthening its cancer pipeline, including European progress for Tecvayli in combination with Darzalex and an acquisition of Firefly Bio to expand oncology research. Johnson & Johnson (JNJ) Expands Cancer Pipeline As Talc Verdict Eases One Risk
• Neutral Sentiment: Several market commentary pieces reiterated bullish Wall Street views and compared J&J favorably with AbbVie, supporting the stock’s valuation narrative but not adding a major new catalyst. Is It Worth Investing in Johnson & Johnson (JNJ) Based on Wall Street's Bullish Views?
• Neutral Sentiment: J&J was also featured in dividend-income and portfolio articles, which helps reinforce its reputation as a stable income stock, though these pieces are unlikely to move shares much on their own. J&J or AbbVie: Which Stock Deserves a Place in Your Portfolio Now?
• Negative Sentiment: No major negative company-specific headline stood out in the latest set of articles; the closest risk item is that ongoing litigation remains a background concern, even as one recent talc verdict went J&J’s way. Johnson & Johnson (JNJ) Expands Cancer Pipeline As Talc Verdict Eases One Risk

Johnson & Johnson Stock Performance

Shares of JNJ stock opened at $262.52 on Friday. The stock has a market capitalization of $631.93 billion, a price-to-earnings ratio of 30.35, a PEG ratio of 2.58 and a beta of 0.24. Johnson & Johnson has a one year low of $154.21 and a one year high of $263.10. The company's 50-day simple moving average is $233.72 and its 200-day simple moving average is $231.26. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.77 and a current ratio of 1.03.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings data on Tuesday, April 14th. The company reported $2.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.68 by $0.02. Johnson & Johnson had a return on equity of 32.60% and a net margin of 21.83%.The firm had revenue of $24.06 billion for the quarter, compared to analysts' expectations of $23.60 billion. During the same quarter in the prior year, the firm posted $2.77 earnings per share. Johnson & Johnson's revenue for the quarter was up 9.9% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. Equities analysts anticipate that Johnson & Johnson will post 11.57 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, June 9th. Investors of record on Tuesday, May 26th were paid a dividend of $1.34 per share. This represents a $5.36 annualized dividend and a yield of 2.0%. This is a boost from Johnson & Johnson's previous quarterly dividend of $1.30. The ex-dividend date was Tuesday, May 26th. Johnson & Johnson's dividend payout ratio (DPR) is 61.97%.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the company. Guggenheim raised their target price on Johnson & Johnson from $266.00 to $270.00 and gave the company a "buy" rating in a report on Friday, June 26th. Stifel Nicolaus upped their price target on Johnson & Johnson from $220.00 to $250.00 and gave the stock a "hold" rating in a report on Wednesday, April 15th. HSBC lifted their price objective on shares of Johnson & Johnson from $265.00 to $280.00 and gave the company a "buy" rating in a research note on Tuesday, March 17th. TD Cowen initiated coverage on shares of Johnson & Johnson in a research report on Wednesday, April 8th. They set a "buy" rating and a $250.00 target price on the stock. Finally, Royal Bank Of Canada restated an "outperform" rating and issued a $265.00 target price on shares of Johnson & Johnson in a research note on Wednesday, April 15th. Twenty equities research analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $256.70.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.